Thermo Fisher Scientific Inc. (TMO) 10-Year Financial Performance & Capital Metrics

TMO • • Industrial / General

HealthcareDiagnostics & ResearchLife Sciences Instrumentation & ToolsLaboratory Equipment & Consumables

AboutThermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.Show more

Revenue $42.88B
EBITDA $10.77B -0.8%
Net Income $6.33B +5.7%
EPS (Diluted) 16.53 +7.0%
Gross Margin 41.34% +3.1%
EBITDA Margin 25.12% -0.8%
Operating Margin 17.87% +2.8%
Net Margin 14.77% +5.6%
ROE 13.13% -0.4%
ROIC 7.48% -1.6%
Debt/Equity 0.66 -15.1%
Interest Coverage 4.63 -7.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 8/9
✓FCF machine: 16.9% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 10.9%
✓Healthy 5Y average net margin of 16.7%
✓Trading near 52-week high

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y9.76%

5Y10.92%

3Y3.03%

TTM3.22%

Profit (Net Income) CAGR

10Y12.83%

5Y11.38%

3Y-6.4%

TTM7.07%

EPS CAGR

10Y13.38%

5Y12.51%

3Y-5.29%

TTM8.59%

ROCE

10Y Avg9.5%

5Y Avg11.52%

3Y Avg9.55%

Latest9.08%

Peer Comparison

Laboratory Equipment & Consumables

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
QGENQiagen N.V.	9.72B	47.20	124.21	0.66%	19.58%	11.11%	5.21%	0.40
RVTYRevvity, Inc.	12.49B	110.14	45.70	0.16%	8.47%	3.23%	4.34%	0.43
DHRDanaher Corporation	166.39B	235.56	44.53	-0.06%	14.43%	6.86%	3.18%	0.35
WATWaters Corporation	23.46B	394.03	36.79	0.07%	20.89%	27.84%	2.64%	0.93
TMOThermo Fisher Scientific Inc.	228.08B	607.08	36.73	0.05%	15.02%	12.84%	3.19%	0.66
MTDMettler-Toledo International Inc.	30.33B	1484.78	36.51	2.22%	21.2%		2.85%
AAgilent Technologies, Inc.	41.48B	146.32	32.02	6.73%	18.75%	19.33%	2.78%	0.50
TWSTTwist Bioscience Corporation	2.46B	40.22	-30.94	20.32%	-23.51%	-17.81%		0.16

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	16.97B	18.27B	20.92B	24.36B	25.54B	32.22B	39.21B	44.91B	42.86B	42.88B
Revenue Growth %	0%	0.08%	0.14%	0.16%	0.05%	0.26%	0.22%	0.15%	-0.05%	0%
Cost of Goods Sold+	9.13B	9.69B	11.24B	13.37B	14.2B	16.19B	19.58B	25.9B	25.66B	25.15B
COGS % of Revenue	0.54%	0.53%	0.54%	0.55%	0.56%	0.5%	0.5%	0.58%	0.6%	0.59%
Gross Profit+	7.84B	8.58B	9.68B	10.99B	11.34B	16.03B	19.63B	19.01B	17.19B	17.73B
Gross Margin %	0.46%	0.47%	0.46%	0.45%	0.44%	0.5%	0.5%	0.42%	0.4%	0.41%
Gross Profit Growth %	-0.01%	0.09%	0.13%	0.14%	0.03%	0.41%	0.23%	-0.03%	-0.1%	0.03%
Operating Expenses+	5.34B	5.72B	6.41B	7.12B	7.08B	8.13B	9.32B	10.49B	9.75B	10.07B
OpEx % of Revenue	0.31%	0.31%	0.31%	0.29%	0.28%	0.25%	0.24%	0.23%	0.23%	0.23%
Selling, General & Admin	4.57B	4.87B	5.41B	6.03B	6.06B	6.95B	7.91B	9.02B	8.41B	8.68B
SG&A % of Revenue	0.27%	0.27%	0.26%	0.25%	0.24%	0.22%	0.2%	0.2%	0.2%	0.2%
Research & Development	692.3M	754.8M	888M	967M	1B	1.18B	1.41B	1.47B	1.34B	1.39B
R&D % of Revenue	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%	0.04%	0.03%	0.03%	0.03%
Other Operating Expenses	85.4M	96.2M	110M	121M	20M	0	0	0	0	0
Operating Income+	2.49B	2.86B	3.27B	3.87B	4.26B	7.9B	10.32B	8.53B	7.45B	7.66B
Operating Margin %	0.15%	0.16%	0.16%	0.16%	0.17%	0.25%	0.26%	0.19%	0.17%	0.18%
Operating Income Growth %	0.06%	0.15%	0.14%	0.19%	0.1%	0.85%	0.31%	-0.17%	-0.13%	0.03%
EBITDA+	4.18B	4.62B	5.3B	6.14B	6.54B	10.22B	12.91B	11.91B	10.85B	10.77B
EBITDA Margin %	0.25%	0.25%	0.25%	0.25%	0.26%	0.32%	0.33%	0.27%	0.25%	0.25%
EBITDA Growth %	0.04%	0.1%	0.15%	0.16%	0.06%	0.56%	0.26%	-0.08%	-0.09%	-0.01%
D&A (Non-Cash Add-back)	1.69B	1.76B	2.03B	2.27B	2.28B	2.33B	2.59B	3.38B	3.41B	3.11B
EBIT	2.35B	2.49B	3.02B	3.93B	4.75B	7.78B	9.38B	8.56B	7.79B	8.69B
Net Interest Income+	-384.3M	-421.2M	-511M	-530M	-452M	-488M	-493M	-454M	-612M	-576M
Interest Income	30.6M	48.4M	81M	137M	224M	65M	43M	272M	879M	1.08B
Interest Expense	414.9M	469.6M	592M	667M	676M	553M	536M	726M	1.49B	1.65B
Other Income/Expense	-558.1M	-835M	-838M	-610M	-189M	-670M	-1.48B	-862M	-1.21B	-667M
Pretax Income+	1.94B	2.02B	2.43B	3.26B	4.07B	7.23B	8.84B	7.66B	6.24B	7B
Pretax Margin %	0.11%	0.11%	0.12%	0.13%	0.16%	0.22%	0.23%	0.17%	0.15%	0.16%
Income Tax+	-43.9M	-1.4M	201M	324M	374M	850M	1.11B	703M	284M	657M
Effective Tax Rate %	1.02%	1%	0.92%	0.9%	0.91%	0.88%	0.87%	0.91%	0.96%	0.91%
Net Income+	1.98B	2.02B	2.23B	2.94B	3.7B	6.38B	7.72B	6.95B	6B	6.33B
Net Margin %	0.12%	0.11%	0.11%	0.12%	0.14%	0.2%	0.2%	0.15%	0.14%	0.15%
Net Income Growth %	0.04%	0.02%	0.1%	0.32%	0.26%	0.72%	0.21%	-0.1%	-0.14%	0.06%
Net Income (Continuing)	1.98B	2.03B	2.23B	2.94B	3.7B	6.38B	7.73B	6.96B	5.96B	6.34B
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	10M	184M	170M	107M	87M
EPS (Diluted)+	4.92	5.09	5.59	7.24	9.17	15.98	19.46	17.64	15.45	16.53
EPS Growth %	0.04%	0.03%	0.1%	0.3%	0.27%	0.74%	0.22%	-0.09%	-0.12%	0.07%
EPS (Basic)	4.96	5.12	5.64	7.31	9.24	16.10	19.61	17.73	15.53	16.58
Diluted Shares Outstanding	401.9M	397.4M	398M	406M	403M	399M	397M	394M	388M	383M
Basic Shares Outstanding	398.7M	394.8M	395M	402M	400M	396M	394M	392M	386M	382M
Dividend Payout Ratio	0.12%	0.12%	0.11%	0.09%	0.08%	0.05%	0.05%	0.07%	0.09%	0.09%

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	5.74B	7.02B	9.42B	10.63B	11.89B	21.96B	20.11B	25.23B	24.59B	22.14B
Cash & Short-Term Investments	452.1M	786M	1.33B	2.1B	2.4B	10.32B	4.48B	8.52B	8.08B	5.57B
Cash Only	452.1M	786M	1.33B	2.1B	2.4B	10.32B	4.48B	8.52B	8.08B	4.01B
Short-Term Investments	0	0	0	0	0	0	0	0	0	1.56B
Accounts Receivable	2.54B	3.05B	3.88B	4.59B	4.95B	6.47B	8.95B	9.43B	9.66B	9.63B
Days Sales Outstanding	54.75	60.9	67.69	68.86	70.77	73.32	83.27	76.61	82.31	81.94
Inventory	1.99B	2.21B	2.97B	3B	3.37B	4.03B	5.05B	5.63B	5.09B	4.98B
Days Inventory Outstanding	79.65	83.34	96.49	82.04	86.64	90.83	94.17	79.39	72.37	72.24
Other Current Assets	752.5M	973M	1.24B	922M	1.17B	1.13B	1.64B	1.64B	1.76B	1.96B
Total Non-Current Assets+	35.09B	38.89B	47.25B	45.61B	46.49B	47.09B	75.01B	71.92B	74.14B	75.18B
Property, Plant & Equipment	2.45B	2.58B	4.05B	4.17B	5.45B	6.69B	9.86B	10.87B	11B	10.79B
Fixed Asset Turnover	6.93x	7.09x	5.17x	5.85x	4.69x	4.82x	3.98x	4.13x	3.89x	3.97x
Goodwill	18.83B	21.33B	25.29B	25.35B	25.71B	26.04B	41.92B	41.2B	44.02B	45.85B
Intangible Assets	12.76B	13.97B	16.68B	14.98B	14.01B	12.69B	20.15B	17.48B	16.67B	15.53B
Long-Term Investments	39M	37M	34M	53M	35M	65M	73M	155M	59M	560M
Other Non-Current Assets	1.02B	974.9M	1.19B	1.06B	1.28B	1.57B	3B	2.22B	2.38B	2.44B
Total Assets+	40.83B	45.91B	56.67B	56.23B	58.38B	69.05B	95.12B	97.15B	98.73B	97.32B
Asset Turnover	0.42x	0.40x	0.37x	0.43x	0.44x	0.47x	0.41x	0.46x	0.43x	0.44x
Asset Growth %	-0.05%	0.12%	0.23%	-0.01%	0.04%	0.18%	0.38%	0.02%	0.02%	-0.01%
Total Current Liabilities+	4.15B	4.87B	7.05B	6.15B	6.2B	10.3B	13.44B	17.01B	14.01B	13.33B
Accounts Payable	822.2M	926.2M	1.43B	1.61B	1.92B	2.17B	2.87B	3.38B	2.87B	3.08B
Days Payables Outstanding	32.88	34.88	46.38	44.09	49.36	49.03	53.45	47.64	40.85	44.68
Short-Term Debt	1.05B	1.26B	2.13B	1.27B	843M	2.81B	2.8B	5.85B	3.87B	2.48B
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	1.14B	1.32B	1.85B	1.47B	1.51B	2.13B	2.68B	3.08B	2.98B	2.94B
Current Ratio	1.38x	1.44x	1.34x	1.73x	1.92x	2.13x	1.50x	1.48x	1.75x	1.66x
Quick Ratio	0.90x	0.99x	0.92x	1.24x	1.38x	1.74x	1.12x	1.15x	1.39x	1.29x
Cash Conversion Cycle	101.52	109.36	117.8	106.8	108.04	115.12	123.98	108.35	113.82	109.5
Total Non-Current Liabilities+	15.34B	19.5B	24.21B	22.5B	22.51B	24.23B	40.71B	36B	37.87B	34.32B
Long-Term Debt	11.42B	15.48B	18.87B	17.72B	17.08B	19.11B	32.15B	28.91B	31.31B	29.06B
Capital Lease Obligations	0	10.3M	10M	9M	571M	626M	1.39B	1.31B	1.24B	1.24B
Deferred Tax Liabilities	2.62B	2.56B	2.77B	2.27B	2.19B	1.79B	3.84B	2.85B	1.92B	1.27B
Other Non-Current Liabilities	1.29B	1.57B	2.57B	2.16B	2.08B	1.94B	2.1B	1.75B	1.9B	1.61B
Total Liabilities	19.48B	24.37B	31.26B	28.65B	28.71B	34.53B	54.15B	53.01B	51.88B	47.65B
Total Debt+	12.47B	16.63B	21.01B	18.99B	18.49B	22.55B	36.34B	36.07B	36.42B	32.77B
Net Debt	12.02B	15.84B	19.65B	16.88B	16.07B	12.21B	31.85B	27.54B	28.34B	28.76B
Debt / Equity	0.58x	0.77x	0.83x	0.69x	0.62x	0.65x	0.89x	0.82x	0.78x	0.66x
Debt / EBITDA	2.98x	3.60x	3.96x	3.09x	2.83x	2.21x	2.81x	3.03x	3.36x	3.04x
Net Debt / EBITDA	2.87x	3.43x	3.71x	2.75x	2.46x	1.19x	2.47x	2.31x	2.61x	2.67x
Interest Coverage	6.01x	6.09x	5.52x	5.81x	6.30x	14.28x	19.25x	11.74x	4.99x	4.63x
Total Equity+	21.35B	21.54B	25.41B	27.59B	29.68B	34.52B	40.98B	44.15B	46.84B	49.67B
Equity Growth %	0.04%	0.01%	0.18%	0.09%	0.08%	0.16%	0.19%	0.08%	0.06%	0.06%
Book Value per Share	53.12	54.20	63.85	67.95	73.64	86.51	103.22	112.05	120.73	129.69
Total Shareholders' Equity	21.35B	21.54B	25.41B	27.59B	29.68B	34.51B	40.79B	43.98B	46.73B	49.58B
Common Stock	411.9M	415.1M	428M	432M	434M	437M	439M	441M	442M	444M
Retained Earnings	12.14B	13.93B	15.91B	18.7B	22.09B	28.12B	35.43B	41.91B	47.36B	53.1B
Treasury Stock	-1.01B	-2.31B	-3.1B	-3.67B	-5.24B	-6.82B	-8.92B	-12.02B	-15.13B	-19.23B
Accumulated OCI	-2B	-2.64B	-2B	-2.5B	-2.68B	-2.81B	-2.33B	-3.1B	-3.22B	-2.7B
Minority Interest	0	0	0	0	0	10M	184M	170M	107M	87M

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	2.82B	3.16B	4B	4.54B	4.97B	8.29B	9.54B	9.15B	8.41B	8.67B
Operating CF Margin %	0.17%	0.17%	0.19%	0.19%	0.19%	0.26%	0.24%	0.2%	0.2%	0.2%
Operating CF Growth %	0.08%	0.12%	0.27%	0.13%	0.09%	0.67%	0.15%	-0.04%	-0.08%	0.03%
Net Income	1.98B	2.03B	2.23B	2.94B	3.7B	6.38B	7.73B	6.96B	6B	6.34B
Depreciation & Amortization	1.69B	1.76B	2.03B	2.27B	2.28B	2.33B	2.59B	3.38B	3.41B	3.11B
Stock-Based Compensation	125M	133.5M	159M	181M	181M	196M	230M	307M	278M	301M
Deferred Taxes	-511.8M	-598.2M	-1.09B	-419M	-348M	-552M	-406M	-995M	-1.3B	-1.21B
Other Non-Cash Items	-14.9M	86.3M	189M	106M	-214M	340M	957M	550M	564M	463M
Working Capital Changes	-449.9M	-248.6M	485M	-530M	-619M	-395M	-1.56B	-1.05B	-537M	-334M
Change in Receivables	-149.4M	-352.2M	-362M	-366M	-225M	-1.3B	-204M	-430M	209M	-171M
Change in Inventory	-140.7M	97.8M	-81M	-324M	-458M	-508M	-1.06B	-825M	598M	-27M
Change in Payables	-2.7M	55.5M	274M	201M	266M	59M	479M	648M	-500M	212M
Cash from Investing+	-1.09B	-5.53B	-7.73B	-1.25B	-1.49B	-1.51B	-21.93B	-2.16B	-5.14B	-5.84B
Capital Expenditures	-422.9M	-444.4M	-508M	-758M	-926M	-1.47B	-2.52B	-2.24B	-1.48B	-1.4B
CapEx % of Revenue	0.02%	0.02%	0.02%	0.03%	0.04%	0.05%	0.06%	0.05%	0.03%	0.03%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	12M	74.4M	-2M	41M	154M	2M	-14M	123M	-73M	317M
Cash from Financing+	-2.62B	2.86B	3.85B	-2.24B	-3.12B	959M	6.58B	-2.81B	-3.62B	-6.79B
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-240.6M	-238.4M	-237M	-266M	-297M	-337M	-395M	-455M	-523M	-583M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	66M	39.8M	-3M	85M	-604M	46M	65M	-9M	56M	194M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	2.39B	2.71B	3.5B	3.79B	4.05B	6.82B	7.02B	6.91B	6.93B	7.27B
FCF Margin %	0.14%	0.15%	0.17%	0.16%	0.16%	0.21%	0.18%	0.15%	0.16%	0.17%
FCF Growth %	0.09%	0.13%	0.29%	0.08%	0.07%	0.68%	0.03%	-0.02%	0%	0.05%
FCF per Share	5.96	6.82	8.79	9.32	10.04	17.08	17.68	17.54	17.85	18.97
FCF Conversion (FCF/Net Income)	1.43x	1.56x	1.80x	1.55x	1.35x	1.30x	1.24x	1.32x	1.40x	1.37x
Interest Paid	0	0	0	687M	790M	471M	555M	667M	1.39B	1.57B
Taxes Paid	0	0	0	591M	896M	1.32B	2.18B	1.23B	1.48B	1.83B

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	9.43%	9.43%	9.48%	11.09%	12.91%	19.86%	20.47%	16.33%	13.18%	13.13%
Return on Invested Capital (ROIC)	5.57%	6.06%	5.94%	6.49%	7.08%	12.81%	12.94%	8.85%	7.6%	7.48%
Gross Margin	46.2%	46.96%	46.27%	45.11%	44.41%	49.75%	50.07%	42.33%	40.12%	41.34%
Net Margin	11.64%	11.06%	10.64%	12.06%	14.47%	19.79%	19.7%	15.47%	13.99%	14.77%
Debt / Equity	0.58x	0.77x	0.83x	0.69x	0.62x	0.65x	0.89x	0.82x	0.78x	0.66x
Interest Coverage	6.01x	6.09x	5.52x	5.81x	6.30x	14.28x	19.25x	11.74x	4.99x	4.63x
FCF Conversion	1.43x	1.56x	1.80x	1.55x	1.35x	1.30x	1.24x	1.32x	1.40x	1.37x
Revenue Growth	0.45%	7.71%	14.47%	16.45%	4.86%	26.14%	21.71%	14.55%	-4.58%	0.05%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Service	-	-	-	5.49B	6.05B	6.91B	8.85B	16.37B	17.61B	17.84B
Service Growth	-	-	-	-	10.13%	14.32%	28.04%	84.94%	7.62%	1.31%
Consumables	-	-	-	12.58B	13.11B	18.53B	22.61B	20.62B	17.6B	17.59B
Consumables Growth	-	-	-	-	4.24%	41.33%	22.03%	-8.78%	-14.68%	-0.06%
Instruments	-	-	-	6.29B	6.39B	6.78B	7.75B	7.92B	7.65B	7.45B
Instruments Growth	-	-	-	-	1.51%	6.14%	14.37%	2.21%	-3.51%	-2.62%
Laboratory Products and Services	6.67B	-	8B	-	-	-	-	-	-	-
Laboratory Products and Services Growth	-	-	-	-	-	-	-	-	-	-
Life Sciences Solutions	4.44B	-	5.73B	-	-	-	-	-	-	-
Life Sciences Solutions Growth	-	-	-	-	-	-	-	-	-	-
Analytical Instruments	3.21B	-	4.85B	-	-	-	-	-	-	-
Analytical Instruments Growth	-	-	-	-	-	-	-	-	-	-
Specialty Diagnostics	3.24B	3.34B	3.49B	-	-	-	-	-	-	-
Specialty Diagnostics Growth	-	2.91%	4.43%	-	-	-	-	-	-	-

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
UNITED STATES	8.61B	9.09B	10.18B	-	-	-	-	-	-	22.5B
UNITED STATES Growth	-	5.56%	12.01%	-	-	-	-	-	-	-
Europe	-	-	-	6.21B	6.36B	8.28B	11.13B	10.76B	10.74B	10.86B
Europe Growth	-	-	-	-	2.30%	30.29%	34.40%	-3.34%	-0.20%	1.08%
Asia Pacific	-	-	-	5.25B	5.52B	5.82B	7.22B	8.12B	7.87B	7.96B
Asia Pacific Growth	-	-	-	-	5.22%	5.39%	23.98%	12.43%	-2.98%	1.05%
All Other Countries	5.3B	4.98B	8.68B	-	-	-	-	-	-	1.56B
All Other Countries Growth	-	-6.04%	74.23%	-	-	-	-	-	-	-
North America	-	-	-	12.14B	12.9B	17.08B	19.66B	24.59B	22.76B	-
North America Growth	-	-	-	-	6.20%	32.45%	15.09%	25.10%	-7.44%	-
Other Regions	-	-	-	750M	764M	1.03B	1.2B	1.44B	1.48B	-
Other Regions Growth	-	-	-	-	1.87%	34.95%	16.39%	20.33%	2.42%	-
CHINA	1.38B	1.73B	2.06B	-	-	-	-	-	-	-
CHINA Growth	-	25.66%	18.99%	-	-	-	-	-	-	-
GERMANY	899.7M	995.8M	-	-	-	-	-	-	-	-
GERMANY Growth	-	10.68%	-	-	-	-	-	-	-	-
JAPAN	-	737.3M	-	-	-	-	-	-	-	-
JAPAN Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Thermo Fisher Scientific Inc. (TMO) has a price-to-earnings (P/E) ratio of 36.7x. This suggests investors expect higher future growth.

Growth & Financials

Thermo Fisher Scientific Inc. (TMO) reported $43.74B in revenue for fiscal year 2024. This represents a 273% increase from $11.73B in 2011.

Thermo Fisher Scientific Inc. (TMO) grew revenue by 0.1% over the past year. Growth has been modest.

Yes, Thermo Fisher Scientific Inc. (TMO) is profitable, generating $6.57B in net income for fiscal year 2024 (14.8% net margin).

Dividend & Returns

Yes, Thermo Fisher Scientific Inc. (TMO) pays a dividend with a yield of 0.25%. This makes it attractive for income-focused investors.

Thermo Fisher Scientific Inc. (TMO) has a return on equity (ROE) of 13.1%. This is reasonable for most industries.

Thermo Fisher Scientific Inc. (TMO) generated $6.11B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...